RT Journal Article
SR Electronic
T1 Can serum biomarkers predict the outcome of systemic therapy for atopic dermatitis?
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.02.20242404
DO 10.1101/2020.12.02.20242404
A1 Hurault, Guillem
A1 Roekevisch, Evelien
A1 Schram, Mandy E.
A1 Szegedi, Krisztina
A1 Kezic, Sanja
A1 Middelkamp-Hup, Maritza A.
A1 Spuls, Phyllis I.
A1 Tanaka, Reiko J.
YR 2020
UL http://medrxiv.org/content/early/2020/12/04/2020.12.02.20242404.abstract
AB Background Atopic dermatitis (AD or eczema) is a most common chronic skin disease. Designing personalised treatment strategies for AD based on patient stratification, rather than the “one-size-fits-all” treatments, is of high clinical relevance. It has been hypothesised that the measurement of biomarkers could help predict therapeutic response for individual patients.Objective We aim to assess whether biomarkers can predict the outcome of systemic therapy.Methods We developed a statistical machine learning predictive model using the data of an already published longitudinal study of 42 patients who received systemic therapy. The data contained 26 serum cytokines measured before the therapy. The model described the dynamics of the latent disease severity and measurement errors to predict AD severity scores (EASI, (o)SCORAD and POEM) two-weeks ahead. We conducted feature selection to identify the most important biomarkers for predicting the AD severity scores.Results We validated our model and confirmed that it outperformed standard time-series forecasting models. Adding biomarkers did not improve predictive performance. Our estimates of the minimum detectable change for the AD severity scores were larger than already published estimates of the minimal clinically important difference.Conclusions Biomarkers had a negligible and non-significant effect for predicting the future AD severity scores and the outcome of the systemic therapy. Instead, a historical record of severity scores provides rich and insightful dynamical information required for prediction of therapeutic responses.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by British Skin Foundation (005/R/18).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the codes are available at https://github.com/ghurault/ssm-eczema-biomarkers